Can metabolic surgery cause severe refractory hypoglycemia?

Question

Hello doctor,

I underwent a duodenal switch metabolic surgery two years ago, and I am now experiencing severe refractory hypoglycemia. My doctors suspect it could be due to nesidioblastosis or islet cell hyperplasia. They have mentioned the possibility of a partial pancreatectomy, but I am very concerned about undergoing surgery again and the risk of losing more of my pancreas. I would like to know if there are any newer or less invasive treatments available for this rare complication. Additionally, are medications like diazoxide or GLP-1 blockers considered safe and effective to try after a duodenal switch? My weight has remained stable, but I experience rapid blood sugar crashes and am finding it difficult to manage.

Kindly advise.

Answer 1

Hello,

Welcome to icliniq.com.

I understand your concern.

You have a history of duodenal switch (DS) metabolic surgery done two years ago and are now experiencing severe refractory hypoglycemia. Based on the clinical picture, your symptoms may be related to post-metabolic hypoglycemia caused by islet cell hyperplasia (nesidioblastosis), a rare condition in adults that can occur following significant weight loss after bariatric procedures.

Treatment considerations:

Islet cell hyperplasia is a known but rare complication following gastric bypass or duodenal switch (DS) surgery. In some cases, the weight loss may unmask an underlying beta cell defect or contribute to pathological islet proliferation, possibly through GLP-1 (glucagon-like peptide 1) mediated pathways.

Partial pancreatectomy (subtotal, typically 75 to 85 percent) has been recommended in adults to control hypoglycemia, especially when medical management fails. However, please note that while this surgical approach often controls blood sugar in the short term, some patients may experience a recurrence of symptoms over time.

Medical management options:

Diazoxide may be considered a non-surgical treatment. It works by activating potassium channels in pancreatic beta cells, thereby reducing calcium influx and suppressing insulin secretion. Though primarily an antihypertensive, it is also used in managing hypoglycemia due to insulin overproduction.

GLP-1 agonists are approved by the Food and Drug Administration (FDA) for managing type 2 diabetes and function by lowering blood glucose levels. However, their use post-DS, particularly in cases of islet cell hyperplasia, should be approached cautiously and under close supervision, as GLP-1 pathways may be involved in the pathogenesis.

At present, there is no definitive medical treatment to reverse islet cell hyperplasia, which is why surgical options are often considered in severe cases. I suggest the following steps:

Discuss the risks and benefits of partial pancreatectomy in detail with your treating endocrinologist and surgeon.
If not already done, continuous glucose monitoring (CGM) can help assess the severity and pattern of hypoglycemic episodes.
Medical therapy with diazoxide may be trialed if not contraindicated.
Any use of GLP-1-based medications should be closely supervised.

I understand your fear regarding further surgery and the potential loss of pancreatic tissue. It’s important to work closely with a multidisciplinary team, including your endocrinologist, bariatric surgeon, and possibly a pancreatic specialist, to develop a personalized and safe treatment plan.

I hope you found this information helpful. Please do not hesitate to reach out for further clarification or ongoing support.

Thank you.